Publication:
Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer

Simple item page
dc.contributor.authorDEDE, FUAT
dc.contributor.authorKAYA, HANDAN
dc.contributor.authorUĞURLU, MUSTAFA ÜMİT
dc.contributor.authorsKaya S., Aktas B., Tanrikulu E., ÖZTÜRK M. S., DEDE F., KAYA H., Ugurlu U., Ozgen Z., Koca S., Halil S., et al.
dc.date.accessioned2023-07-05T09:12:31Z
dc.date.available2023-07-05T09:12:31Z
dc.date.issued2017-09-01
dc.description.abstract© 2017 Zerbinis Publications. All rights reserved.Purpose: Current evaluation of response to neoadjuvant chemotherapy (NAC) shows that it could achieve pathological complete response (pCR). The purpose of this study was to assess the consistency of maximum uptake values (SUVmax) changes and pCR in hormone-positive locally advanced breast cancer (LABC). Methods: Ninety hormone-positive LABC patients treated at Marmara University Medical Oncology Clinic, Istanbul, Turkey, between 2009 and 2015 were retrospectively studied. All eligible patients (n=51) received NAC (4-8 cycles) and were evaluated for pCR. 18F-fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG-PET/CT) scan was performed before and after the completion of NAC. The relative changes of SUVmax both in the primary tumor and the axilla were assessed for consistency with pCR. Results: The patient median age was 46 years (range 26-76). The patients 13.7% achieved pCR. Values of >50% (n=40) and 75% SUVmax changes could achieve pCR of 20%. Interestingly, most patients with complete metabolic response did not achieve pCR (81%). The difference of the Ki67 levels before and after NAC, tumor localization, HER-2 positivity, menopausal status, grade of differentiation, lymphovascular and perineural invasion were not associated with pCR. Conclusion: SUVmax changes in later cycles of NAC as commonly practised in oncology clinics were not consistent with pCR (p=1.0). Complete metabolic response may not be associated with pCR in hormone-positive LABC. However, almost 80% of patients had >50% decrease in SUVmax and may still have a chance for conservative surgery and less postoperative morbidity. Therefore, 18F-FDG-PET/CT may still have a role to evaluate the tumor response with a need of larger studies and analysis for cost-effectiveness.
dc.identifier.citationKaya S., Aktas B., Tanrikulu E., ÖZTÜRK M. S., DEDE F., KAYA H., Ugurlu U., Ozgen Z., Koca S., Halil S., et al., "Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer", Journal of B.U.ON., cilt.22, sa.5, ss.1191-1198, 2017
dc.identifier.endpage1198
dc.identifier.issn1107-0625
dc.identifier.issue5
dc.identifier.startpage1191
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85045576735&origin=inward
dc.identifier.urihttps://hdl.handle.net/11424/290818
dc.identifier.volume22
dc.language.isoeng
dc.relation.ispartofJournal of B.U.ON.
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectOnkoloji
dc.subjectNükleer Tıp
dc.subjectYaşam Bilimleri
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectSitogenetik
dc.subjectTemel Bilimler
dc.subjectMedicine
dc.subjectHealth Sciences
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectHematology
dc.subjectOncology
dc.subjectNuclear medicine
dc.subjectLife Sciences
dc.subjectMolecular Biology and Genetics
dc.subjectCytogenetic
dc.subjectNatural Sciences
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectMoleküler Biyoloji ve Genetik
dc.subjectRADYOLOJİ, NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME
dc.subjectHEMATOLOJİ
dc.subjectONKOLOJİ
dc.subjectBİYOKİMYA VE MOLEKÜLER BİYOLOJİ
dc.subjectClinical Medicine (MED)
dc.subjectLife Sciences (LIFE)
dc.subjectCLINICAL MEDICINE
dc.subjectMOLECULAR BIOLOGY & GENETICS
dc.subjectRADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
dc.subjectHEMATOLOGY
dc.subjectONCOLOGY
dc.subjectBIOCHEMISTRY & MOLECULAR BIOLOGY
dc.subjectRadyoloji, Nükleer Tıp ve Görüntüleme
dc.subjectKanser Araştırmaları
dc.subjectRadiology, Nuclear Medicine and Imaging
dc.subjectCancer Research
dc.subject18F-FDG-PET/CT
dc.subjectHormone-positive
dc.subjectLocally advanced breast cancer
dc.subjectNeoadjuvant chemotherapy
dc.subjectPathologic complete response
dc.subject18F-FDG-PET/CT
dc.subjecthormone-positive
dc.subjectlocally advanced breast cancer
dc.subjectneoadjuvant chemotherapy
dc.subjectpathologic complete response
dc.titleChanges in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer
dc.typearticle
dspace.entity.typePublication
local.avesis.ide7969652-4ab5-4afe-b924-6cfadc03b199
local.indexed.atPUBMED
local.indexed.atSCOPUS
relation.isAuthorOfPublicationdbe5967c-c66d-4e50-97c6-0334cb93f7da
relation.isAuthorOfPublication0bf301ff-2544-4a5e-b38b-b43084d6c255
relation.isAuthorOfPublication76044dc9-a441-4103-b46d-5d995fec91d4
relation.isAuthorOfPublication.latestForDiscoverydbe5967c-c66d-4e50-97c6-0334cb93f7da

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
file.pdf
Size:
570.53 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs